The European Commission has granted marketing authorisation for Servier’s Valdoxan® / Thymanax® (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes.
Following approval from the European Commission, Valdoxan is expected to become commercially available in European countries in the coming months.